Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cabaletta Bio Inc
(NQ:
CABA
)
13.34
-0.63 (-4.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,178,220
Open
13.90
Bid (Size)
13.00 (9)
Ask (Size)
13.36 (4)
Prev. Close
13.97
Today's Range
13.08 - 14.28
52wk Range
7.690 - 26.35
Shares Outstanding
31,355,723
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023
March 21, 2024
CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Recap: Cabaletta Bio Q4 Earnings
March 21, 2024
Via
Benzinga
Performance
YTD
-39.80%
-39.80%
1 Month
-26.38%
-26.38%
3 Month
-31.52%
-31.52%
6 Month
-0.60%
-0.60%
1 Year
+59.00%
+59.00%
More News
Read More
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
March 20, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 12/8
December 08, 2023
Via
Investor Brand Network
Analyst Ratings for Cabaletta Bio
November 29, 2023
Via
Benzinga
Where Cabaletta Bio Stands With Analysts
November 10, 2023
Via
Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 11/9
November 09, 2023
Via
Investor Brand Network
Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
March 06, 2024
Via
Benzinga
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 27, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
February 01, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio: Q3 Earnings Insights
November 09, 2023
Via
Benzinga
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Cabaletta Bio
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 22, 2024
Via
Benzinga
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
January 08, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday
December 07, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Leslie's Posts Weak Earnings, Joins Las Vegas Sands, Verve Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
November 29, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 28, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Crude Oil Surges 2%; Tharimmune Shares Plummet
November 28, 2023
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 28, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 28, 2023
Via
Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Cabaletta Bio: Here's What You Need To Know
November 15, 2023
Via
Benzinga
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
November 06, 2023
From
Cellares
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.